NO323955B1 - Natriumsalt av et azoderivat av 5-aminosalisylsyre, farmasoytisk preparat, anvendelse av natriumsaltet for fremstilling av et medikament og fremgangsmate for fremstilling av nariumsaltet - Google Patents
Natriumsalt av et azoderivat av 5-aminosalisylsyre, farmasoytisk preparat, anvendelse av natriumsaltet for fremstilling av et medikament og fremgangsmate for fremstilling av nariumsaltet Download PDFInfo
- Publication number
- NO323955B1 NO323955B1 NO20024878A NO20024878A NO323955B1 NO 323955 B1 NO323955 B1 NO 323955B1 NO 20024878 A NO20024878 A NO 20024878A NO 20024878 A NO20024878 A NO 20024878A NO 323955 B1 NO323955 B1 NO 323955B1
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- methyl
- sodium salt
- azo
- hydroxy
- Prior art date
Links
- 159000000000 sodium salts Chemical class 0.000 title claims description 83
- 238000000034 method Methods 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title claims description 6
- 229960004963 mesalazine Drugs 0.000 title description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- AYEAMZDTWLXZIJ-MUNUSVGFSA-N Cc1nc2cnccc2n1CC(CC1)CCN1C(=O)C=C(c1ccccc1)c(cc1)ccc1\N=N/c1cc(C(O)=O)c(O)cc1 Chemical compound Cc1nc2cnccc2n1CC(CC1)CCN1C(=O)C=C(c1ccccc1)c(cc1)ccc1\N=N/c1cc(C(O)=O)c(O)cc1 AYEAMZDTWLXZIJ-MUNUSVGFSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002329 infrared spectrum Methods 0.000 claims description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000005711 Benzoic acid Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 235000010233 benzoic acid Nutrition 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- -1 2-methyl-1H-imidazo-[4,5 -c]pyridin-1-yl Chemical group 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- FMYHFHVAPZDDPJ-UHFFFAOYSA-N ethanol;ethyl acetate;hydrate Chemical compound O.CCO.CCOC(C)=O FMYHFHVAPZDDPJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 210000003608 fece Anatomy 0.000 description 11
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JWQVOMJORQXNME-UHFFFAOYSA-N 2-methyl-3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC(C)=NC2=C1 JWQVOMJORQXNME-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000996A ES2165803B1 (es) | 2000-04-10 | 2000-04-10 | Nueva sal de un derivado azo del acido 5-aminosalicilico |
| PCT/EP2001/004109 WO2001077109A2 (en) | 2000-04-10 | 2001-04-10 | Sodium salt of an azo derivative of 5-aminosalicylic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20024878D0 NO20024878D0 (no) | 2002-10-09 |
| NO20024878L NO20024878L (no) | 2002-12-05 |
| NO323955B1 true NO323955B1 (no) | 2007-07-23 |
Family
ID=8493217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024878A NO323955B1 (no) | 2000-04-10 | 2002-10-09 | Natriumsalt av et azoderivat av 5-aminosalisylsyre, farmasoytisk preparat, anvendelse av natriumsaltet for fremstilling av et medikament og fremgangsmate for fremstilling av nariumsaltet |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6809087B2 (pt) |
| EP (1) | EP1272490B1 (pt) |
| JP (2) | JP4597463B2 (pt) |
| KR (2) | KR100859296B1 (pt) |
| AR (1) | AR033363A1 (pt) |
| AT (1) | ATE372999T1 (pt) |
| AU (1) | AU2001273937A1 (pt) |
| BR (1) | BR0109935A (pt) |
| CA (1) | CA2405741C (pt) |
| CY (1) | CY1107090T1 (pt) |
| DE (1) | DE60130444T2 (pt) |
| DK (1) | DK1272490T3 (pt) |
| ES (2) | ES2165803B1 (pt) |
| HK (1) | HK1052184B (pt) |
| MX (1) | MXPA02009934A (pt) |
| NO (1) | NO323955B1 (pt) |
| PT (1) | PT1272490E (pt) |
| WO (1) | WO2001077109A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312806A (en) * | 1981-03-02 | 1982-01-26 | G. D. Searle & Co. | Method and compounds for treating inflammatory bowel disease |
| IE70217B1 (en) * | 1990-08-15 | 1996-10-30 | British Bio Technology | Benzimidazole derivatives process for their preparation and application |
| ES2087038B1 (es) * | 1994-11-07 | 1997-03-16 | Uriach & Cia Sa J | Nuevas piperidinas con actividad antagonista del paf. |
| AU6987596A (en) * | 1995-09-08 | 1997-03-27 | J. Uriach & Cia S.A. | Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease |
-
2000
- 2000-04-10 ES ES200000996A patent/ES2165803B1/es not_active Expired - Fee Related
-
2001
- 2001-04-09 AR ARP010101685A patent/AR033363A1/es not_active Application Discontinuation
- 2001-04-10 US US10/257,262 patent/US6809087B2/en not_active Expired - Fee Related
- 2001-04-10 ES ES01940316T patent/ES2291320T3/es not_active Expired - Lifetime
- 2001-04-10 PT PT01940316T patent/PT1272490E/pt unknown
- 2001-04-10 KR KR1020027013473A patent/KR100859296B1/ko not_active IP Right Cessation
- 2001-04-10 AT AT01940316T patent/ATE372999T1/de active
- 2001-04-10 BR BR0109935-3A patent/BR0109935A/pt not_active IP Right Cessation
- 2001-04-10 JP JP2001575582A patent/JP4597463B2/ja not_active Expired - Fee Related
- 2001-04-10 EP EP01940316A patent/EP1272490B1/en not_active Expired - Lifetime
- 2001-04-10 WO PCT/EP2001/004109 patent/WO2001077109A2/en active IP Right Grant
- 2001-04-10 DE DE60130444T patent/DE60130444T2/de not_active Expired - Lifetime
- 2001-04-10 CA CA2405741A patent/CA2405741C/en not_active Expired - Fee Related
- 2001-04-10 MX MXPA02009934A patent/MXPA02009934A/es active IP Right Grant
- 2001-04-10 KR KR1020087012339A patent/KR100933646B1/ko not_active IP Right Cessation
- 2001-04-10 AU AU2001273937A patent/AU2001273937A1/en not_active Abandoned
- 2001-04-10 DK DK01940316T patent/DK1272490T3/da active
-
2002
- 2002-10-09 NO NO20024878A patent/NO323955B1/no not_active IP Right Cessation
-
2003
- 2003-06-21 HK HK03104473.5A patent/HK1052184B/zh not_active IP Right Cessation
-
2007
- 2007-12-07 CY CY20071101589T patent/CY1107090T1/el unknown
-
2010
- 2010-04-15 JP JP2010094382A patent/JP2010159293A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1272490E (pt) | 2007-11-08 |
| CA2405741C (en) | 2010-11-02 |
| DE60130444D1 (de) | 2007-10-25 |
| JP2010159293A (ja) | 2010-07-22 |
| DK1272490T3 (da) | 2008-01-21 |
| ATE372999T1 (de) | 2007-09-15 |
| WO2001077109A2 (en) | 2001-10-18 |
| NO20024878D0 (no) | 2002-10-09 |
| CY1107090T1 (el) | 2012-10-24 |
| EP1272490A2 (en) | 2003-01-08 |
| AU2001273937A1 (en) | 2001-10-23 |
| KR20020084306A (ko) | 2002-11-05 |
| NO20024878L (no) | 2002-12-05 |
| HK1052184B (zh) | 2007-11-16 |
| ES2291320T3 (es) | 2008-03-01 |
| WO2001077109A3 (en) | 2001-12-27 |
| KR100933646B1 (ko) | 2009-12-23 |
| ES2165803A1 (es) | 2002-03-16 |
| JP2003530397A (ja) | 2003-10-14 |
| EP1272490B1 (en) | 2007-09-12 |
| BR0109935A (pt) | 2003-05-27 |
| AR033363A1 (es) | 2003-12-17 |
| ES2165803B1 (es) | 2003-09-16 |
| HK1052184A1 (en) | 2003-09-05 |
| KR100859296B1 (ko) | 2008-09-19 |
| CA2405741A1 (en) | 2001-10-18 |
| US6809087B2 (en) | 2004-10-26 |
| JP4597463B2 (ja) | 2010-12-15 |
| KR20080053417A (ko) | 2008-06-12 |
| MXPA02009934A (es) | 2004-08-19 |
| DE60130444T2 (de) | 2008-06-05 |
| US20030176401A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3438099B1 (en) | Vortioxetine pamoic acid salt and crystal form thereof | |
| DE60103394T2 (de) | 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung | |
| KR20120104627A (ko) | 나트륨 2-(5-브로모-4-(4-시클로프로필나프탈렌-1-일)-4ｈ-1,2,4-트리아졸-3-일티오)아세테이트의 다형태, 결정질 및 중간상 형태 및 그의 용도 | |
| CN110431130A (zh) | 多晶型化合物和其用途 | |
| US11951100B2 (en) | Formulations of RBP4 inhibitors and methods of use | |
| TW202203926A (zh) | 嘧啶環己基糖皮質素受體調節劑之調配物 | |
| NO323955B1 (no) | Natriumsalt av et azoderivat av 5-aminosalisylsyre, farmasoytisk preparat, anvendelse av natriumsaltet for fremstilling av et medikament og fremgangsmate for fremstilling av nariumsaltet | |
| US9593117B2 (en) | Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
| TWI378929B (en) | Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses | |
| TW201900646A (zh) | 5型磷酸二酯酶抑制劑的甲磺酸鹽多晶物及其製備方法和應用 | |
| US9593116B2 (en) | Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
| US9598413B2 (en) | Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
| US9464086B2 (en) | Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
| TW201925192A (zh) | Urat1抑制劑的晶型及其製備方法 | |
| US11795180B2 (en) | Formulation of a pan-JAK inhibitor | |
| CN115960097A (zh) | 瑞普替尼新晶型及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |